label multicenter Phase

Related by string. * labels . Labels . labeled . labeling : Multi Protocol Label . label Def Jam . Multiprotocol Label Switching MPLS . label dose escalation / Multicenter : multicenter Phase II . multicenter randomized double . Multicenter Randomized Double . multicenter randomized / phases . Phases . phase : Phase III clinical trials . Phase III trials . Phase III clinical * *

Related by context. Frequent words. (Click for all words.) 75 label dose escalation 71 multicenter randomized 66 Phase III randomized 65 ATTRACT 63 randomized Phase III 63 multicenter randomized double 63 multicenter 62 phase IIb 62 active comparator 62 investigational oral 62 pivotal Phase 61 randomized controlled 61 randomized Phase 61 Phase 2a clinical 61 phase IIa 61 multicentre 61 dose escalation trial 61 Phase IIa clinical 61 Phase 2a 60 placebo controlled 60 placebo controlled randomized 60 Phase 1b 60 Phase 1b trial 60 Phase IIa trial 60 randomized placebo controlled 60 Phase Ib 60 Phase 1b clinical 60 prospective randomized 59 Phase 2b 59 Phase 2a trial 59 Phase 2b study 59 Phase IIb trial 59 BAY #-# 59 DURATION 59 multicenter clinical 59 Phase IIa 59 blind randomized placebo 59 Randomized 59 blinded placebo controlled 58 phase 2a 58 pivotal Phase III 58 Phase IIb 58 Phase 2b clinical 58 confirmatory Phase III 58 safety tolerability pharmacokinetics 58 randomized controlled clinical 58 Phase 2b trial 58 blind randomized 57 TELCYTA 57 Phase IIb clinical 57 bosentan 57 double blind placebo 57 tocilizumab 57 unblinded 57 noninferiority 57 dose escalation study 56 Phase III clinical 56 orally bioavailable 56 SCH # 56 6R BH4 56 Phase III pivotal 56 placebo controlled trials 56 randomized clinical 56 randomized double 56 substudy 56 PF # [001] 56 randomized #:# 56 HGS ETR1 56 INCB# [002] 56 nitazoxanide 56 randomized 56 rNAPc2 56 PROMACTA 56 RG# [001] 56 intravenous formulation 56 LEVADEX 55 Monotherapy 55 Initiates Phase 55 Phase 1a 55 Bortezomib 55 pharmacodynamics 55 blind placebo controlled 55 Clinical Trial Results 55 ACTEMRA 55 Pegasys R 55 dose escalation 55 dose cohorts 55 SEROQUEL 55 dabigatran etexilate 54 axitinib 54 tolerability 54 dose regimens 54 intravenously administered 54 Phase III 54 sapacitabine 54 IMC A# 54 randomized clinical trials 54 alvimopan 54 Amigal 54 adalimumab 54 topical formulation

Back to home page